Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3

被引：0
|
作者：
Touzeau, Cyrille [1 ]
Weisel, Katja [2 ]
Bahlis, Nizar [3 ]
Quach, Hang [4 ]
Hamilton, Finn [5 ]
Wang, Shen-wu [5 ]
Leip, Eric [5 ]
Viqueira, Andrea [6 ]
O'Brien, Thomas [5 ]
Rodriguez-Otero, Paula [7 ]
机构：
[1] CHU Nantes, Nantes, France
[2] Univ Canc Ctr Hamburg, Hamburg, Germany
[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[4] Univ Melbourne, Vincents Hosp Melbourne, Parkville, Vic, Australia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer SLU, Madrid, Spain
[7] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [21] Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Tomasson, Michael H.
    Bahlis, Nizar J.
    Costello, Caitlin
    Raje, Noopur S.
    Levy, Moshe Y.
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Damore, Michael A.
    Jiang, Sibo
    Xie, Tao
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Gasparetto, Cristina
    Chu, Michael
    Dalovisio, Andrew Peter
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies
    Ishida, Tadao
    Yokoyama, Hisayuki
    Suzuki, Kenshi
    Ito, Satoshi
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Viqueira, Andrea
    White, Jane Liang
    Take, Kazumi
    Moribe, Toyoki
    Iida, Shinsuke
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S186 - S187
  • [23] The effect of elranatamab on patient-reported outcomes in patients with relapsed/refractory multiple myeloma naive and exposed to BCMA-directed therapies: results from the MagnetisMM-3 study
    Mohty, Mohamad
    Bahlis, Nizar
    Nooka, Ajay
    DiBonaventura, Marco
    Ren, Jinma
    Conte, Umberto
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S300 - S301
  • [24] Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
    Costa, Luciano J.
    LeBlanc, Thomas W.
    Tesch, Hans
    Sonneveld, Pieter
    Kyle, Ryan P.
    Sinyavskaya, Liliya
    Hlavacek, Patrick
    Meche, Aster
    Ren, Jinma
    Schepart, Alex
    Aydin, Didem
    Nador, Guido
    DiBonaventura, Marco daCosta
    FUTURE ONCOLOGY, 2024, 20 (17) : 1175 - 1189
  • [25] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
    Bahlis, Nizar Jacques
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay K.
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander M.
    BLOOD, 2022, 140
  • [26] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
    Avet-Loiseau, Herve
    Casneuf, Tineke
    Chiu, Christopher
    Laubach, Jacob P.
    Lee, Je-Jung
    Moreau, Philippe
    Plesner, Torben
    Nahi, Hareth
    Khokhar, Nushmia Z.
    Qi, Ming
    Schecter, Jordan
    Carlton, Victoria
    Qin, Xiang
    Liu, Kevin
    Wu, Kaida
    Zhuang, Sen H.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [27] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Maiolino, Angelo
    Da Costa, Elaine Sobral
    Orfao, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, Afshin E.
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos
    Viqueira, Andrea
    Lesokhin, Alexander M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
  • [29] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Raab, M. S.
    Haenel, M.
    Mohty, M.
    Tomasson, M. H.
    Arnulf, B.
    Bahlis, N. J.
    Prince, H. M.
    Niesvizky, R.
    Rodriguez-Otero, P.
    Martinez-Lopez, J.
    Koehne, G.
    Jethava, Y.
    Gabayan, A. E.
    Stevens, D. A.
    Nooka, A. K.
    Raje, N.
    Iida, S.
    Leip, E.
    Conte, U.
    Czibere, A.
    Viqueira, A.
    Lesokhin, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
  • [30] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
    Raje, Noopur S.
    Leleu, Xavier P.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345